Yaman Gibran, MD
Internal Medicine · Montrose, PANPI 1477127744
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 32.3% of the total.
Across 56 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$316
- Bayer$166
- Lilly USA, LLC$144
- Exact Sciences$93
- Pfizer$85
- E.r. Squibb & Sons, L.L.C.$51
- plus $125 from 6 others
What the payments were for
- Food & beverage$978100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $316 |
| Bayer | 9 | $166 |
| Lilly USA, LLC | 11 | $144 |
| Exact Sciences | 5 | $93 |
| Pfizer | 4 | $85 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| AstraZeneca | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
How this compares
$978 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 31 | $162 |
| Atorvastatin Calcium | 15 | $160 |
| Methylprednisolone | 14 | $78 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $74 |
| Cephalexin | 12 | $41 |
| Prednisone | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Montrose
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.